NCT03833934View on ClinicalTrials.gov

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance

CompletedOBSERVATIONAL
Enrollment

62

Participants

Timeline

Start Date

January 23, 2019

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Non-Small Cell Lung Cancer
Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Addario Lung Cancer Medical Institute

OTHER

NCT03833934 - Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance | Biotech Hunter | Biotech Hunter